FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-2.51%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$311M
AUM Growth
+$311M
(-16%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-5.16%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
1
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$16.6M |
Top Sells
| 1 |
Lyell Immunopharma
LYEL
|
$24.1M |
| 2 |
Nurix Therapeutics
NRIX
|
$8.58M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $116M | 37.17% |
9,671,643
| – | – |
|
|
2
Lyell Immunopharma
LYEL
$220M
| $73.3M | 23.57% |
10,000,000
-3,282,181
| -25% | -$24.1M |
|
3
Aclaris Therapeutics
ACRS
$223M
| $44.2M | 14.21% |
2,808,034
| – | – |
|
4
Kura Oncology
KURA
$732M
| $25.3M | 8.13% |
1,849,947
| – | – |
|
5
Pharvaris
PHVS
$1.41B
| $24.9M | 8.01% |
3,246,926
| – | – |
|
|
6
Syndax Pharmaceuticals
SNDX
$1.39B
| $16.6M | 5.33% |
+690,000
| New | +$16.6M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $6.26M | 2.01% |
1,787,094
| – | – |
|
8
Quantum-Si Incorporated
QSI
$217M
| $4.87M | 1.57% |
1,771,249
| – | – |
|
|
9
Nurix Therapeutics
NRIX
$723M
| – | – |
-677,143
| Closed | -$8.58M |
|